NuSight Medical introduced new device for dry eye treatment

22 June 2018 (Last Updated November 26th, 2018 11:09)

Ophthalmic care company NuSight Medical has introduced a new medical device called the NuLids System to treat dry eyes.

Ophthalmic care company NuSight Medical has introduced a new medical device called the NuLids System to treat dry eyes.

Unveiled at the American Optometric Association meeting in Denver, NuLids is said to improve dry eye conditions by gently stimulating and rejuvenating the Meibomian glands in the eye.

NuSight Medical president and CEO Rob Foster said: “Patients benefit from improved tear film stability, comfort, and lubrication that combat dry eye. Doctors gain an important therapy while helping to build their practice.

“The company stated that under the NuLids I and NuLids II clinical studies, nearly 95% of patients surveyed following a 30-day trial were said to be satisfied or very satisfied with the treatment.”

“And, because NuLids is sold only through licensed eye care practitioners, doctors are in control of the therapy while patients perform the treatment at home, improving practice efficiency.”

NuSight Medical founder and chairman John Olkowski said that nearly 86% of dry eye patients’ Meibomian gland function are damaged leading to unstable tear film and its premature breakdown.

The NuLids facilitates the production and flow of meibum at the gland reducing signs of dry eye.

At a clinical study, the NuLids System bettered Tear Breakup Time by 65%, while Meibomian Glands Yielding Liquid Secretions improved by 81%.

Most of the patients in the study also reported significant improvement in their dry eye conditions following two weeks of daily usage.

Taking around one minute per day, the NuLids process can be carried out with the in-office procedures performed by eye doctors.

NuSight claimed that the NuLids system is convenient to use without any known side effects.

The company also stated that under the NuLids I and NuLids II clinical studies, nearly 95% of patients surveyed following a 30-day trial were said to be satisfied or very satisfied with the treatment.